Novartis to invest USD 15 million for stem cell therapies
Advertisement
Gamida cell, an Israel based stem cell therapy company will see an additional investment of 15 million dollars from its early investor, the Swiss drug maker Novartis. Novartis is reported to buy another 2.5 percent in Israel's Gamida Cell
Novartis had earlier invested 35 million dollars in the company, in a deal recognised to mark it's 15 percent holding stake in the company. The acquisition is now has the potential to reach a value of 600 million dollars, if Novartis exercises a complete buy out option in 2016.
Novartis had earlier invested 35 million dollars in the company, in a deal recognised to mark it's 15 percent holding stake in the company. The acquisition is now has the potential to reach a value of 600 million dollars, if Novartis exercises a complete buy out option in 2016.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.